[{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Abingworth LLP","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Abingworth LLP","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Abingworth LLP"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"NeuBase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"NT0200","moa":"DMPK protein degradation","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ NeuBase Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Vera Therapeutics \/ NeuBase Therapeutics"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.070000000000000007,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"MAU868","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Intravenous","sponsorNew":"Vera Therapeutics \/ Vera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Vera Therapeutics"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MAU868","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"MAU868","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"BLyS\/APRIL","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.12,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Nephrology","graph2":"Phase III","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Atacicept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Vera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Atacicept","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Vera Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Vera Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Vera Therapeutics \/ J.P. Morgan"}]

Find Clinical Drug Pipeline Developments & Deals by Vera Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The net proceeds will fund the development of VT-001 (atacicept), a BAFF/APRIL inhibitor currently under evaluation for treating patients with IgA nephropathy.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 29, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $300.0 million

                          Deal Type : Public Offering

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : VT-001 (atacicept) is a BLyS/APRIL inhibitor protein drug candidate, which is currently being evaluated for the treatment of patients with IgA nephropathy.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 02, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : VT-001 (atacicept) is a BLyS/APRIL inhibitor protein drug candidate, which is currently being evaluated for the treatment of patients with IgA nephropathy.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 12, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : VT-001 (atacicept) has been granted breakthrough therapy designation for the treatment of IgAN. It is currently being evaluated in late-stage clinical trials.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 28, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The net proceeds will fund Phase 3 clinical trial of VT-001 (atacicept), a fusion protein given subcutaneously, for IgAN, along with regulatory submissions and potential commercial launch preparation.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 01, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $287.5 million

                          Deal Type : Public Offering

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Proceeds will fund VT-001 (atacicept) development, targeting autoantibodies in autoimmune diseases like IgAN (Berger's disease) and lupus nephritis.

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 29, 2024

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $250.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : VT-001 (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator and a proliferation-in...

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          June 07, 2023

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune disea...

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 06, 2023

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $115.0 million

                          Deal Type : Public Offering

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The offering will be used to fund phase 3 trial of VT-001 (atacicept), a fusion protein that blocks both BLyS and a proliferation inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune disea...

                          Brand Name : VT-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 01, 2023

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : J.P. Morgan

                          Deal Size : $100.0 million

                          Deal Type : Public Offering

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : TACI-IG (atacicept) is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor receptor that binds to the cytokines B lymphocyte stimulator (BlyS) and a prolifer...

                          Brand Name : TACI-IG

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          January 30, 2023

                          Lead Product(s) : Atacicept

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank